Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720
      QxMD      Google Scholar   
Citation:
Leukemia vol 25 (5)
Year:
2011
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
Book Volume:
Parents:
432  
Children:
None
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA047577, U10 CA032291, CA33601, CA77597, CA04457, CA101140, CA11789, U10 CA077658, CA02599, CA77406, CA47577, CA47555, CA32291, CA29165, CA41287, U10 CA035279, CA03927, U10 CA031946, U10 CA033601, CA59518, CA26806, CA45389, CA45808, CA35279, CA12046, CA35421, CA16450, U10 CA101140, CA77440, U10 CA041287, CA45564, CA04326, CA08025, CA74811, CA21060, CA47559, CA47642, CA45418, CA77658, CA37135, CA77298, CA31983, CA31946, U10 CA003927, CA07968  
Corr. Author:
 
Authors:
                       
Primary Study
CALGB-9720
Secondary Studies:
Phases:
3
Keywords:
acute myeloid leukemia, age, daunorubicin, dose escalation, etoposide